Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations

Clinical Cancer Research

Volumn 15, Issue 13, 2009, Pages 4493-4498

  Morita, Satoshi ^a   Okamoto, Isamu ^b   Kobayashi, Kunihiko ^d   Yamazaki, Koichi ^f   Asahina, Hajime ^f   Inoue, Akira ^g   Hagiwara, Koichi ^e   Sunaga, Noriaki ⁱ   Yanagitani, Noriko ⁱ   Hida, Toyoaki ^j   Yoshida, Kimihide ^j   Hirashima, Tomonori ^c   Yasumoto, Kosei ^k   Sugio, Kenji ^k   Mitsudomi, Tetsuya ^j   Fukuoka, Masahiro ^b   Nukiwa, Toshihiro ^h  

^a YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^b KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c OSAKA PREFECTURAL MEDICAL CENTER FOR RESPIRATORY AND ALLERGIC DISEASES   (Japan)

^d SAITAMA MEDICAL UNIVERSITY INTERNATIONAL MEDICAL CENTER   (Japan)

^e SAITAMA MEDICAL UNIVERSITY   (Japan)

^f HOKKAIDO UNIVERSITY   (Japan)

^g TOHOKU UNIVERSITY HOSPITAL   (Japan)

^h TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

ⁱ GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^j AICHI CANCER CENTER HOSPITAL   (Japan)

^k UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER SURVIVAL; CLINICAL TRIAL; CORRELATION ANALYSIS; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INTERSTITIAL LUNG DISEASE; JAPAN; LIVER DYSFUNCTION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RASH; SIDE EFFECT; SOMATIC MUTATION; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS, PHASE II AS TOPIC; FEMALE; GENES, ERBB-1; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; QUINAZOLINES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 67650378948     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-0391     Document Type: Article

References (37)

1. Jemal A, Siegel R,Ward E, et al. Cancer statistics, 2008. CA CancerJClin 2008;58:71-96.
2. Clinical practice guidelines for the treatment of unresectable non-small-cell lungca ncer. Adopted on May 16, 1997 by theAmerican Society of Clinical Oncology. JClin Oncol 1997;15:2996-3018.
3. Socinski MA, Crowell R, HensingTE, et al.Treatment of non-small cell lungc ancer, stage IV: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007;132:277-89S.
4. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic reviewand meta-analysis of individual patient data from 16 randomized controlled trials. JClin Oncol 2008;26:4617- 25.
5. Hirsch FR,Varella-Garcia M, Bunn PA, Jr., et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. JClin Oncol 2003;21:3798-807.
6. Suzuki S, DobashiY, Sakurai H, Nishikawa K,Hanawa M, Ooi A. Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lungc arcinomas. An immunohistochemical and fluorescence in situ hybridization study. Cancer 2005;103:1265-73.
7. Fukuoka M,Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lungc ancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 2003;21:2237-46.
8. Shepherd FA, Rodrigues Pereira J, CiuleanuT, et al. Erlotinib in previously treated non-small-cell lungca ncer. NEnglJMed 2005;353:123- 32.
9. Maruyama R, Nishiwaki Y, TamuraT, et al. Phase III study,V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lungca ncer. JClin Oncol 2008;26:4244- 52.
10. Kim ES, HirshV, MokT, et al. Gefitinib versus docetaxel in previously treated non-small-cell lungca ncer (INTEREST): a randomised phase III trial. Lancet 2008;372:1809-18.
11. Ando M, Okamoto I,Yamamoto N, et al. Predictive factors for interstitial lungd isease, antitumor response, and survival in non-small-cell lungc ancer patients treated with gefitinib. J Clin Oncol 2006;24: 2549-56.
12. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlyingr esponsiveness of non-small-cell lungc ancer to gefitinib. NEngl JMed 2004;350:2129-39.
13. PaezJG, Janne PA, LeeJC, et al. EGFRmutations in lungc ancer : correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
14. PaoW, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci US A 2004;101:13306-11.
15. KosakaT,YatabeY, Endoh H, Kuwano H,TakahashiT, Mitsudomi T. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 2004;64:8919-23.
16. Shigematsu H, Lin L,Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. JNatl Cancer Inst 2005;97:339-46.
17. Mitsudomi T, KosakaT, Endoh H, et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lungca ncer with postoperative recurrence. JClin Oncol 2005;23:2513-20.
18. Mitsudomi T,Yatabe Y. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lungc ancer. Cancer Sci 2007;98:1817-24.
19. Inoue A, Suzuki T, Fukuhara T, et al. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lungc ancer with epidermal growth factor receptor gene mutations. JClin Oncol 2006;24:3340-6.
20. Asahina H, Yamazaki K, Kinoshita I, et al. A phase II trial of gefitinib as first-line therapy for advanced non-small cell lungca ncer with epidermal growth factor receptor mutations. Br J Cancer 2006;95: 998-1004.
21. Sutani A, Nagai Y, Udagawa K, et al. Gefitinib for non-small-cell lungc ancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp. BrJCancer 2006;95:1483-9.
22. Yoshida K,YatabeY, Park JY, et al. Prospective validation for prediction of gefitinib sensitivity by epidermal growth factor receptor gene mutation in patients with non-small cell lungc ancer. J Thorac Oncol 2007;2:22-8.
23. SunagaN,TomizawaY,Yanagitani N, et al. Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFRmutations, irrespective of previous chemotherapy. LungC ancer 2007;56:383- 9.
24. Tamura K, Okamoto I, KashiiT, et al.Multicentre prospective phase II trial of gefitinib for advanced nonsmall cell lungcan cer with epidermal growth factor receptormutations: results of theWestJapanThoracic Oncology Group trial (WJTOG0403). Br J Cancer 2008;98:907-14.
25. Sugio K, Uramoto H, OnitsukaT, et al. Prospective phase II study of gefitinib in non-small cell lung cancer with epidermal growth factor receptor gene mutations. LungC ancer. In press.
26. Yatabe Y, Hida T, Horio Y, Kosaka T, Takahashi T, Mitsudomi T. A rapid, sensitive assay to detect EGFR mutation in small biopsy specimens from lungca ncer. JMol Diagn2006;8:335-41.
27. Nagai Y, Miyazawa H, Huqun, et al. Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lungca ncer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res 2005;65:7276- 82.
28. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. JNatl Cancer Inst 2000;92:205-16.
29. Rosell R,Taron M, Sanchez JJ, Paz-Ares L. Setting the benchmark for tailoringtr eatment with EGFR tyrosine kinase inhibitors. Future Oncol 2007;3:277-83.
30. Sequist LV, Martins RG, Spigel D, et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harborings omatic EGFR mutations. J Clin Oncol 2008;26:2442- 9.
31. Takano T, Ohe Y, Sakamoto H, et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lungc ancer. JClinOncol 2005;23:6829-37.
32. Han SW, KimTY, HwangP G, et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lungcancer patients treated with gefitinib. JClin Oncol 2005;23:2493- 501.
33. Jackman DM,Yeap BY, Sequist LV, et al. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in nonsmall cell lungcan cer patients treated with gefitinib or erlotinib. Clin Cancer Res 2006;12:3908-14.
34. Riely GJ, PaoW, Pham D, et al. Clinical course of patientswith non-small cell lungc ancer and epidermal growth factor receptor exon19 and exon 21mutations treated with gefitinib or erlotinib. Clin Cancer Res 2006;12:839-44.
35. TakanoT, Fukui T, OheY, et al. EGFR mutations predict survival benefit from gefitinib in patients with advanced lungad enocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan. JClin Oncol 2008;26:5589-95.
36. Wu JY,Yu CJ,YangC H, et al. First- or second-line therapy with gefitinib produces equal survival in nonsmall cell lungc ancer. Am J Respir Crit Care Med 2008;178:847-53.
37. Mok T,Wu YL, Thongprasert S, et al. Phase III, randomised, open-label, first-line study of gefitinib vs carboplatin/paclitaxel (C/P) in clinically selected patients with advanced non-small-cell lungc ancer (NSCLC). Ann Oncol 2008;19:viii4.